PAOA – 5 mg

Brand:
Cayman
CAS:
537034-15-4
Storage:
-20
UN-No:
Non-Hazardous - /

PAOA is a selective histone deacetylase (HDAC) inhibitor with IC50 values of 199 and 69 nM for HDAC1 and HDAC3, respectively.{37081} It is selective for HDAC1 and HDAC3, having IC50 values greater than 1.59 μM for HDAC2, 4, 5, 7, and 8 in a cell-free enzyme assay. In vitro, PAOA induces histone H3 and H4 hyperacetylation.{37083} PAOA improves the metabolic deficit exhibited by murine striatal cells isolated from HdhQ111 knock-in mice in a dose-dependent manner and reduces eye neurodegeneration in a D. melanogaster model of Huntington’s disease.{37081} In vivo, PAOA prevents formation of Huntingtin (Htt) protein aggregates in the brain and reduces the cognitive deficits in the N171-82Q mouse model of Huntington’s disease.{37082}  

 

Available on backorder

SKU: 22942 - 5 mg Category:

Description

A selective HDAC1/3 inhibitor (IC50s = 199 and 69 nM for HDAC1 and HDAC3, respectively); selective for HDAC1 and HDAC3 (IC50 = >1.59 μM for HDAC2, 4, 5, 7, and 8 in a cell-free enzyme assay); improves the metabolic deficit exhibited by murine striatal cells isolated from HdhQ111 knock-in mice in a dose-dependent manner; reduces eye neurodegeneration in D. melanogaster model of Huntington’s disease; prevents formation of Htt aggregates in the brain and reduces the cognitive deficits in the N171-82Q mouse model of Huntington’s disease


Formal name: N1-(2-aminophenyl)-N7-phenyl-heptanediamide

Synonyms:  Histone Deacetylase Inhibitor IV

Molecular weight: 325.4

CAS: 537034-15-4

Purity: ≥95%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Inhibitors|Deacetylases||Research Area|Epigenetics, Transcription, & Translation|Erasers|Histone Deacetylation||Research Area|Neuroscience|Behavioral Neuroscience|Learning & Memory||Research Area|Neuroscience|Neurodegenerative Disorders